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A B S T R A C T
Radiation-induced DNA damage activates the DNA damage response (DDR). DDR up-
regulation may predict radio-resistance and increase the risk of early local recurrence
despite radiotherapy in early stage breast cancers. In 1755 early stage breast cancers,
DDR signalling [ATM, ATR, total Ckh1, Chk1 phosphorylated at serine345 (pChk1), Chk2,
p53], base excision repair [PARP1, POLb, XRCC1, FEN1, SMUG1], non-homologous end
joining (Ku70/Ku80, DNA-PKcs) and homologous recombination [RAD51, BRCA1, gH2AX,
BLM, WRN, RECQL5, PTEN] protein expression was correlated to time to early local recur-
rence. Pre-clinically, radio-sensitization by inhibition of Chk1 activation by ATR inhibitor
(VE-821) and inhibition of Chk1 (V158411) were investigated in MDA-MB-231 (p53 mutant)
and MCF-7 (p53 wild-type) breast cancer cells. In the whole cohort, 208/1755 patients
(11.9%) developed local recurrence of which 126 (61%) developed local recurrence within
5 years of initiation of primary therapy. Of the 20 markers tested, only pChk1 and p53
significantly associated with early local recurrence (p value ¼ 0.015 and 0.010, respectively).
When analysed together, high cytoplasmic pChk1-nuclear pChk1 (p ¼ 0.039), high cyto-
plasmic pChk1-p53 (p ¼ 0.004) and high nuclear pChk1-p53 (p ¼ 0.029) co-expression
remain significantly linked to early local recurrence. In multivariate analysis, cytoplasmic
pChk1 level independently predicted early local recurrence (p ¼ 0.025). In patients who
received adjuvant local radiotherapy (n ¼ 949), p53 (p ¼ 0.014) and high cytoplasmic
pChk1-p53 (p ¼ 0.017) remain associated with early local recurrence. Pre-clinically, radio-
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sensitisation by VE-821 or V158411 was observed in both MCF-7 and MDA-MB-231 cells and
was more pronounced in MCF-7 cells. We conclude that pChk1 is a predictive biomarker of
radiotherapy resistance and early local recurrence.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.
1. Introduction
Despite advances in surgery, adjuvant radiation and systemic
therapies, 10e20% of early stage breast cancer patients will
develop local recurrence (della Rovere and Benson, 2002;
Gieni et al., 2012; Schnitt, 2003; van der Leij et al., 2012). Estab-
lished risk factors for early local recurrence include young age
at diagnosis (#40 years), larger tumour size, multifocal dis-
ease, axillary nodal involvement, extra-capsular tumour
extension, positive margin, high grade, definite positive
lympho-vascular invasion, HER-2 overexpression, ER nega-
tivity, and extensive intra-ductal component (della Rovere
and Benson, 2002; Gieni et al., 2012; Schnitt, 2003; van der
Leij et al., 2012). Local recurrence may herald the emergence
of radio-resistant cancer clones with aggressive biology that
may adversely impact upon patient outcomes (Clarke et al.,
2005). Therefore, mining for predictive biomarkers for devel-
opment of radio-resistance is a high priority. Ionizing radia-
tion (IR) induced DNA damage is a key mechanism for
cytotoxicity and therapeutic efficacy in tumours (Derks
et al., 2014; Santivasi and Xia, 2014). However, the ability of
tumour cells to initiate an effective DNA damage response
(DDR), by activating multiple DNA damage signalling and
repair pathways, may result in resistance to radiotherapy
and ultimately influence the emergence of local recurrence
in patients (Derks et al., 2014; Santivasi and Xia, 2014).
In the current study, we have comprehensively investi-
gated the expression of a panel of DNA repair factors involved
in the DDR: DNA damage signalling (ATM, ATR, total Chk1,
Chk1 phosphorylated at serine345 (here in referred to as
pChk1) (Tian et al., 2015), CHK2, p53, base excision repair
(PARP1, POLb, XRCC1, FEN1, SMUG1) (Wallace, 2014), non-
homologous end joining (Ku70/Ku80, DNA-PKcs) (Williams
et al., 2014) and homologous recombination (RAD51, BRCA1,
gH2AX, BLM, WRN, RECQL5, PTEN) (Liu and Huang, 2014) for
local recurrence prediction in early stage breast cancers. In
addition, work was also undertaken to test the blockade of
CHK1 activation through ATR inhibition (VE-821, Vertex phar-
macuticals) (Josse et al., 2014) and direct CHK1 inhibition
(V158411, Vernalis R&D Ltd) (Bryant et al., 2014; Stokes et al.,
2009) in MDA-MB-231 and MCF-7 breast cancer cell lines.
2. Methods
2.1. Clinical study
2.1.1. Patients
Demographics of the study population are summarised in
Table 1. The cohort comprised of primary operable early-
stage (stage IeIII) invasive breast cancers from patients
treated by breast-conserving surgery (wide local excision)
and radiotherapy at Nottingham University Hospitals. Infor-
mation on clinical history and outcome is prospectivelymain-
tained and patients were assessed in a standardised manner
for clinical history and tumour characteristics. Local
recurrence-free survival was defined as the time interval (in
months) between the start of primary treatment and date of
first histological confirmation of recurrent cancer (invasive
or in-situ) at the vicinity of the treated breast. Distant
metastasis-free survival was defined as the time interval (in
months) between the start of primary treatment and date of
distant disease relapse. Breast Cancer Specific Survival
(BCSS) is defined as the time (in months) from the date of pri-
mary surgery to the date of breast cancer related death.
In this early breast cancer cohort, 949 patients had received
adjuvant local radiotherapy. Patients were managed in accor-
dance to a uniform protocol, where all underwent wide local
excision followed by radiotherapy which was given in daily 2
Gray (Gy) fractions, to a total dose of 50e55 Gy over 5 weeks.
Thirty one patients received radiotherapy in the context of
clinical trials investigating altered fractionation schedules.
Radiotherapy was delivered to the whole breast. During the
treatment period a ‘‘boost’’ to the tumour bed was not
routinely given, however a “16 Gy boost” was given to six pa-
tients. Patients received systemic adjuvant treatment on the
basis of Nottingham Prognostic Index (NPI), estrogen receptor
(ER) status and menopausal status. Patients with an NPI score
<3.4 did not receive adjuvant treatment. ER negative or pre-
menopausal cases with an NPI score of 3.4 or more were can-
didates for cyclophosphamide, Methotrexate and 5-
Flourouracil (CMF) combination chemotherapy; ER positive
cases received Tamoxifen for a period of 5 years.
This study is reported according to REMARK (Reporting
Recommendations for Tumour Marker Prognostic Studies)
Table 1 eMultivariate analysis (Time to local recurrence).
P value Exp(B) 95.0% CI for Exp(B)
Lower Upper
Time to local recurrence
Lymph node status 0.710 0.920 0.591 1.431
Tumour size 0.592 0.888 0.575 1.371
Tumour Grade 0.396 1.165 0.818 1.659
ER 0.410 0.791 0.453 1.381
Vascular Invasion 0.216 1.488 0.793 2.794
p53 0.315 1.278 0.792 2.062
pChk1 (cytoplasmic) 0.025 1.639 1.065 2.522
Bold ¼ statistically significant.
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criteria (McShane et al., 2005). Ethical approval for the study
was granted by Nottingham Research Ethics committee 2 un-
der the title “Development of a molecular genetic classifica-
tion of breast cancer” (C202313).
2.1.2. Tissue microarrays (TMAs) and
immunohistochemistry (IHC)
Tumours were arrayed in tissue microarrays (TMAs) con-
structed with 0.6 mm cores from the periphery of the tumours.
The TMAs were immunohistochemically stained for a panel of
DNA repair markers (Supplementary Table S2) as previously
described (Abdel-Fatah et al., 2014, 2015; Albarakati et al., 2015;
Arora et al., 2015). Immunohistochemical staining was per-
formed using the Novolink Max Polymer Detection System
(RE7280-K: 1250 tests), and the Leica Bond Primary Antibody
Diluent (AR9352), eachused according to themanufacturer’s in-
structions (LeicaMicrosystems).Thetissuesectionsweredepar-
affinised with xylene and rehydrated through five descending
concentrations of alcohol (100%, 90%, 70%, 50% and 30%), two
minutes each. Pre-treatment antigen retrieval was performed
using sodium citrate buffer (pH 6.0) and heated for 20 min at
95 $C in amicrowave (Whirpool JT359 Jet Chef 1000W). Negative
and positive (by omission of the primary antibody and IgG-
matched serum) controls were included in each run. The nega-
tive control ensured that all the stainingwas produced from the
specific interaction between antibody and antigen.
2.1.3. Evaluation of immunostaining
The tumour cores were evaluated by two scorers (TAF and AA)
and the concordance between the two scorer was excellent
(k ¼ 0.79). Only TMA cores with adequate invasive tumour tis-
sue (>15% tumour) were scored, leaving out those with inade-
quate invasive tissue. Whole field inspection of the core was
scored and intensities of nuclear staining were grouped as fol-
lows: 0 ¼ no staining, 1 ¼ weak staining, 2 ¼ moderate stain-
ing, 3 ¼ strong staining. The percentage of each category
was estimated (0e100%). H-score (range 0e300) was calculated
by multiplying intensity of staining and percentage staining.
Cut-offs for individual markers are summarised in
Supplementary Table 2.
2.1.4. Statistical analysis
Data analysiswas performed using SPSS (SPSS, version 17 Chi-
cago, IL). Cumulative local recurrence, distant metastasis and
survival probabilities were estimated using the KaplaneMeier
method, and differences between survival rates were tested
for significance using the log-rank test. Multivariate analysis
for survival was performed using the Cox proportional hazard
model. The proportional hazards assumption was tested us-
ing standard logelog plots. Hazard ratios (HR) and 95% confi-
dence intervals (95% CI) were estimated for each variable. All
testswere two-sidedwith a 95%CI and a p value< 0.05 consid-
ered significant.
2.2. Pre-clinical study
2.2.1. Tissue culture and reagents
MCF7 and MDA-MB-231 breast cancer cell lines were obtained
from ATCC (Manassas, VA, USA)and cultured with Gibco!
RPMI 1640 medium (Gibco, Grand Island, NY, USA) supple-
mented with 10% fetal bovine serum (SigmaeAldrich, St.
Louis, MO, USA), and 10mg/ml streptomycin/penicillin (Gibco)
in an atmosphere of 20% O2 and 5% CO2. Cells were authenti-
cated by STR profiling by LGC standards (Teddington, UK) and
confirmed to be mycoplasma free (MycoAlert, Lonza, Basel,
Switzerland) and used within 30 passages of authentication.
VE-821, a specific ATR inhibitor was provided by Vertex phar-
maceuticals (Josse et al., 2014). V158411, a specific CHK1 inhib-
itor was provided by Vernalis R&D Ltd (Bryant et al., 2014;
Stokes et al., 2009). VE-821 and V158411 were dissolved in
DMSO as stock solutions at 10 mM stored at % 20 $C.
2.2.2. Chk1 knockdown
For Chk1 knockdown, Chk1 siRNA targeting Chk1 and the
mock siRNA control (Dharmacon, GE Biosciences, Pittsburgh,
PA, USA) were transfected into cells by InterferIN (Polyplus
transfection, Illkirch, France) according to manufacturer’s
protocol. Western blotting was performed to confirm CHK1
knockdown.
2.2.3. Cell growth assay
MCF7 cells or MDA-MB-231 cells were seeded into 96-well tis-
sue culture plates and allowed to adhere for 24 h. Cells were
treated with increasing concentrations of VE-821 for 24 h
before being allowed to grow in fresh media for 5 more days.
Cells were fixed using Carnoy’s fixative and stained with
DAPI before being solubilised and the DAPI fluorescence
measured. Data is mean data from 3 individual replicates.
Mean GI50 values & S.E.M. were calculated using GraphPad
Prism version 6.0.
2.2.4. Clonogenic cell survival assays
MCF7 andMDA-MB-231 cells were seeded into 5 cm tissue cul-
ture plates and allowed to adhere for 24 h. Following 1 h pre-
treatment with 1 mM VE-821 or 50 nM or 150 nM V185411 or a
vehicle control of 0.1% DMSO, cells were irradiated. Pre-
treatment was to allow drugs to enter cell prior to irradiation.
Since activation of checkpoints would come after IR damage
the cells were co incubated for a further 24 h in the presence
of drug prior to seeding for colony formation. Ionising radia-
tion (X-irradiation; IR) was administered using a GulmayMed-
ical Xstrahl RS320 X-irradiator (GulmayMedical, Chertsey, UK)
at a rate of 3.15 Gy/min. After 24 h, cells were harvested,
counted and re-seeded at low density for colony formation
in drug-free medium. After 2 weeks, colonies were fixed using
Carnoy’s fixative, stained using 1% crystal violet, and counted.
All experiments were performed atleast thrice. LD50 values
(dose of IR where 50% of cells no longer survive) were calcu-
lated from each experiment and the potentiation factor at
50% cell kill (PF50) was calculated.
2.2.5. Cell cycle progression by FACS
Exponentially growing MCF7 or MDA-MB-231 were seeded
into 10 cm tissue culture dishes and allowed to adhere for
24 h. Where indicated, cells were pre-treated with 1 mM VE-
821, 50 nM V158411 or 150 nM V158411 for 1 h before IR (2
Gys) or mock treatment. After 24 h, media from cells was
collected, the cells washed and harvested and fixed and
frozen in ice cold methanol overnight. Cells were stained
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with 200 mg/ml PI and 200 mg/ml RNAase A in PBS and sam-
ples run using a FACScalibur counting a minimum of 20000
events. Single cell populations were then gated into phases
of the cell cycle by DNA content (A e one represtentative
example from each cell line) and the resulting profiles ana-
lysed using Cyflogic software (B emean & S.D. of three indi-
vidual experiments).
3. Results
3.1. DNA repair and local recurrence (whole cohort)
We initially investigated local recurrence in the whole cohort
irrespective of whether they received adjuvant radiotherapy
or not. Within the studied patients’ cohort, 208/1755 patients
(11.9%) developed local recurrence. Among patients who
developed local recurrence, 126/208 (61%) patients developed
early local recurrence within 5-years of primary treatment,
indicating the presence of an aggressive tumour. We pro-
ceeded to investigate DNA repair expression and time to early
local recurrence in this cohort. KaplaneMeier plots for time to
local recurrence for all the DNA repair markers are summar-
ised in Supplementary Figure. S1AeS1W. Of the twenty
markers investigated (Supplementary Figure S1AeS1X), only
pChk1 and p53 protein levels were significantly associated
with shorter time to local recurrence (Figures 1 and 2).
High levels of cytoplasmic pChk1 (p¼ 0.015) (Figure 1B) was
significantly associated with shorter time to local recurrence.
However, nuclear pChk1 level was not significantly associated
with local recurrence (Figure 1C). When nuclear and cyto-
plasmic expression of pChk1 were combined together, we
observed that tumours with a high nuclear/cytoplasmic
pChk1 level were more likely to have shorter time to local
recurrence, compared to tumours with low nuclear/cyto-
plasmic pChk1 level (Figure 1D). We also investigated total
non-phosphorylated form of Chk1. Tumours exhibited only
nuclear staining. There was no cytoplasmic expression.
Chk1 expression did not influence time to local recurrence
(Supplementary Fig. S1X).
High nuclear p53 was associated with early local recur-
rence compared to tumours with low p53 expression
(p ¼ 0.010) (Figure 1E). When p53 and pChk1 were combined,
high p53/high cytoplasmic pChk1 level were more likely to
have shorter time to local recurrence compared to tumours
with low p53/low cytoplasmic pChk1 level (Figure 2A)
(p ¼ 0.004). In addition, high p53/high nuclear pChk1 level
were more likely to have shorter time to local recurrence
compared to tumours with low p53/low nuclear pChk1 level
(Figure 2B) p ¼ 0.029).
In multivariate analysis, high cytoplasmic pChk1 was an
independent predictor of early local recurrence (Table 1).
Taken together, these data suggest that cytoplasmic pChk1
is a key predictor of early local recurrence in patients with
early breast cancers. In addition, p53 status could further
stratify patients into two subsets; those who have local recur-
rence or not. We then proceeded to investigate if p53 and
pChk1 expression status also has an impact on distant metas-
tasis and BCSS.
3.2. p53, pChk1, time to distant metastasis and survival
(whole cohort)
Neither cytoplasmic pChk1 alone nor nuclear pChk1 alone
influenced distant metastasis (Supplementary Figure S2A,
S2C). High cytoplasmic pChk1 alone was associated with
poor survival (p ¼ 0.040) (Supplementary Figure S2B) but nu-
clear pChk1 alone was not associated with BCSS survival
(Supplementary Figure S2D). Moreover, when combined
together, cytoplasmic pChk1/nuclear pChk1 did not influence
metastasis (Supplementary Figure S2E). However, BCSS was
poor in patients with tumours showing high cytoplasmic
pChk1 and low nuclear pChk1 expression (Supplementary
Figure S2F) (p ¼ 0.042).
High p53 was significantly associated with time to distant
metastasis (p < 0.001) and BCSS (p < 0.001) (Supplementary
Figure S2G, S2H). When p53 and CHK1 were combined
together, we observed that tumours with high p53 and high
pChk1 (nuclear as well as cytoplasmic) were significantly
associated with shorter time to distant metastasis and BCSS
(Supplementary Figure S2IeS2L) (p < 0.005).
Together, the data suggest that p53 and pChk1 expression
result in aggressive breast cancer phenotype with adverse
prognostic significance.
3.3. p53 and pChk1 predict resistance to adjuvant
radiotherapy
To investigate whether p53 and pChk1 also predict resistance
to adjuvant radiotherapy we proceeded to sub-group analysis
in 949 (out of 1755) patients who had received adjuvant radio-
therapy. 92/949 (9.69%) had local recurrence. Tumours with
high p53 was associated with early local recurrence compared
to tumours with low p53 expression (p ¼ 0.014)
(Supplementary Figure S3A). When combined with pChk1, tu-
mours with high p53/high cytoplasmic pChk1 was associated
with early local recurrence (p ¼ 0.017) (Supplementary
Figure S3D). p53/pChk1 (nuclear) (Supplementary
Figure S3E), pChk1 (nuclear alone) (Supplementary
Figure S3B) or pChk1 (cytoplasmic alone) (Supplementary
Figure S3C) alone did not influence early local recurrence.
Taken together the data provides evidence that p53 as well
as p53/pChk1 (cytoplasmic) co-expression are promising bio-
markers of radiotherapy response.
3.4. Targeting the CHK1 pathway for radio-
sensitization
The clinical data presented here provides evidence that
pChk1 has prognostic and predictive significance in breast
cancer. Therefore Chk1 pathway targeting may be a prom-
ising radio-sensitising approach. To address this possibility,
we followed two pharmacological approaches; ATR inhibi-
tion by VE-821 which prevents Chk1 activation (by blocking
phosphorylation on serine345) (Josse et al., 2014) and direct
Chk1 inhibition by V158411 which blocks auto-
phosphorylation of Chk1 on Serine296 (Bryant et al., 2014;
Stokes et al., 2009).
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3.4.1. VE-821 mediated inhibition of Chk1 phosphorylation at
serine345 and radio-sensitivity
ATR is activated by single stranded (ss)-double stranded (ds)
DNA junctions generated at sites of DNA damage. Activated
ATR in turn phosphorylates Chk1 at Ser 345 (Fokas et al.,
2014;Marechal and Zou, 2013). VE-821 is a highly specific small
molecule inhibitor of ATR (Josse et al., 2014). We have previ-
ously shown that VE-821 blocks phosphorylation of Chk1 at
serine345 and is a biomarker of ATR inhibition (Abdel-Fatah
et al., 2015; Chen et al., 2015). We initially investigated VE-
821 treatment alone in MCF-7 and MDA-MB-231 cells. VE-821
was growth inhibitory in both breast cancer cells (Figure 3A)
and this effect was greater in p53 mutant MDA-MB-231 cells
compared to p53 wild type MCF7 cells [GI50 (concentration
required to reduce 50% of growth) ¼ 1.1 & 0.2 mM and
2.8 & 0.1 mM, respectively]. We then proceed to IR combination
studies. As shown in Figure 3B and 3C, VE-821 significantly
potentiated IR in MCF7 cells and MDA-MB-231 cells. The
dose of IR at which 50% of cells were killed (LD50) was interpo-
lated in the presence and absence of 1 mM VE-821 and the fold
potentiation calculated. VE-821 significantly potentiated IR in
MCF7 cells by almost 3-fold (2-way ANOVA, p < 0.0001) and in
MDA-MB-231 by almost 2-fold (2-way ANOVA, p ¼ 0.0012;
Figure 3D; Supplementary Table S3).
As both p53 and ATR are implicated in different cell cycle
checkpoints (Gudkov and Komarova, 2003; Zhang and
Hunter, 2014), radiopotentiation by VE-821 may be linked to
changes in cell cycle profiles. To establish whether any differ-
ences in radiopotentiation were due to cell cycle effects, each
cell line was treated with a clinically relevant (2 Gy) dose of IR
with or without VE-821 and cell cycle profiles were assessed
(Figure 3E and Supplementary Figure S4). VE-821 caused a
modest increase in the G1 population in MCF7 (8.2 & 7.8%)
and MDA-MB-231 cells (10.5 & 1.0%), but reduced S-phase ar-
rest by approximately 8% in both lines whichwould be consis-
tent with the growth inhibitory effect seen in (Figure 3C and
D). This reduction in S arrest accompanied a small reduction
in the G2 fraction. In contrast, and consistent with mutated
p53, IR did not induce any G1 arrest in MDA-MB-231 cells but
induced a substantial (22.1 & 18.6%) increase in G2 arrest
which was completely abrogated by VE-821. IR did not induce
G2 arrest in MCF7 cells, but VE-821 did cause a substantial
reduction in the S and G2 fractions of irradiated cells suggest-
ing that there may be an element of S/G2 checkpoint activa-
tion by IR that was abrogated by VE-821 in these cells.
Interestingly, the combination of IR and VE-821 in MCF7 cells
caused a substantial (37.5 & 30%) increase in G1 arrested cells
which would be consistent with the induction of p53 by this
combination.
Activated ATR not only phosphorylates Chk1 at Ser 345 but
also several other target proteins involved in homologous
recombination repair and DNA cross link repair (Fokas et al.,
2014; Marechal and Zou, 2013). Therefore, to clarify whether
the radio-potentiation is contributed by CHK1 mediated
events, we investigated V185411, a highly specific CHK1
inhibitor.
3.4.2. Chk1 inhibition and radio-sensitivity
We initially attempted to generate Chk1 knockdown (KD)
breast cancer cell lines (Figure 4A). Figure 4B quantifies this
knockdown of Chk1 by siRNA in comparison to cell line sam-
ples treated with control scrambled siRNA. There was 80%
knockdown after 48 h and more than 98% knockdown after 5
days. In parallel with the samples prepared for western blot-
ting a clonogenic assay was performed in control cells, those
treated with scrambled siRNA and with Chk1 siRNA for 48 h.
This shows that there was no clonogenic survival after 2
weeks in cells treated for 48 h with Chk1 siRNA (Figure 4C).
Therefore it was not possible to test radio-sensitisation in
Chk1 KD cells.
We proceeded to investigate V158411, a highly specific, and
potent inhibitor of Chk1 [in vitrowith IC50 of 3.5 nM and in vivo
V158411 inhibited the etoposide induced auto-
phosphorylation of Chk1 on Serine296 with an IC50 of 48 nM]
Figure 2 e Kaplan Meier curves showing time taken to local recurrence based on A. p53 & pChk1 cytoplasmic co-expression; B. p53 & pChk1
nuclear co-expression.
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(Bryant et al., 2014; Stokes et al., 2009). As shown in Figure 4D
and E, a concentration dependent potentiation of IR toxicity
was seen in bothMCF-7 andMDA-MB-231 cells. InMCF-7 cells,
potentiation at 2 Gy was 1.6 fold and 1.9 fold with 50 nM or
150 nM V158411, respectively. In MCF-7 cells, potentiation at
10 Gy was 1.5 fold and 6 fold with 50 nM or 150 nM V158411,
respectively. In MDA-MB-231 cells, potentiation at 2 Gy was
1.2 fold and 1.4 fold with 50 nM or 150 nM V158411, respec-
tively. In MDA-MB-231 cells, potentiation at 10 Gy was 1.6
fold and 5 fold with 50 nM or 150 nM V158411, respectively.
Previous studies have shown that G1 check point does not
operate in p53 mutant cells and cells are reliant upon S and
G2 checkpoints mediated through Chk1 for maintaining
genomic stability (Levesque et al., 2005). We therefore investi-
gated cell cycle progression in V158411 (50 nM or 150 nM)
treated MDA-MB-231 cells either alone or in combination
with radiotherapy. As shown in Figure 4E, there was a reduc-
tion in cells in G2-phase in VE158411 treated cells compared to
untreated control cells. Whereas in IR treated cells, as ex-
pected, the cell accumulated in G2-phase of the cell cycle.
However, with IR þ VE158411 combination therapy, there
was a reduction in cells in G2-phase. Taken together, the
data provides evidence that VE158411 blocks Chk1 mediated
G2 arrest in p53 deficient breast cancer cell.
4. Discussion
IR induces a wide variety of DNA lesions including oxidative
base damage, abasic (AP) sites, deoxyribose damage, single
strand breaks (SSBs) and double strand breaks (DSBs). An
additional feature of IR damage is the introduction of
Figure 3 e Blockade of CHK1 phosphorylation by VE-821 (ATR inhibitor) and radio-potentiation. A. Effect of VE-821 on breast cancer cell
growth. For clonogenic assays, data are mean ± standard deviation from three separate experiments in MCF7 (B) and MDA-MB-231 (C). D. LD50
values (dose of IR where 50% of cells no longer survive) were calculated from each experiment and the potentiation factor at 50% cell kill (PF50)
was calculated (see Supplementary Table S3 for further details). E. Exponentially growing MCF7 or MDA-MB-231 were seeded into 10 cm tissue
culture dishes and allowed to adhere for 24 h. Where indicated, cells were pre-treated with 1 mM VE-821 for 1 h before IR (2 Grays) or mock
treatment. After 24 h, media from cells was collected, the cells washed and harvested and fixed and frozen in ice cold methanol overnight. Cells
were stained with 200 mg/ml PI and 200 mg/ml RNAase A in PBS and samples run using a FACScalibur counting a minimum of 20000 events.
Single cell populations were then gated into phases of the cell cycle by DNA content. The resulting FACS profiles analysed using Cyflogic software
(mean ± S.D. of three individual experiments) is show here.
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clustered DNA lesions through reactive species generation
(Kavanagh et al., 2013; Santivasi and Xia, 2014; Willers et al.,
2004). These DNA lesions would require initiation of multiple
signal transduction cascades that will dictate the final fate of a
cell; whether to tolerate DNA damage, initiate DNA repair or
undergo apoptosis (Kavanagh et al., 2013; Santivasi and Xia,
2014; Willers et al., 2004). In the current study, we have
comprehensively investigated DNA damage signalling and
repair in a cohort of invasive breast cancer patients who
developed early local recurrence which is a feature of radio-
resistant breast cancers. We have observed that p53 and
pChk1 are key determinants of radio-sensitivity in breast can-
cer patients receiving adjuvant radiotherapy. Interestingly, we
did not observe any significant associations with other key
DNA repair markers including ATM, ATR, total Chk1, Chk2,
PARP1, POLb, XRCC1, FEN1, SMUG1, Ku70/Ku80, DNA-PKcs,
RAD51, BRCA1, gH2AX, BLM, WRN, RECQL5 and PTEN.
The tumour suppressor p53 is centrally involved in the co-
ordination of cell cycle regulation, DNA repair and apoptosis
in response to IR (Fei and El-Deiry, 2003; Gudkov and Komar-
ova, 2003). p53 is typically involved in IR-induced G1 arrest
and may also have roles in S and G2/M phases of the cell cycle
(Fei and El-Deiry, 2003; Gudkov and Komarova, 2003). P53
mediated apoptosis is a central determinant of radio-
sensitivity (Fei and El-Deiry, 2003; Gudkov and Komarova,
2003). In addition, p53 is involved in IR-induced growth arrest.
Mutation in p53 is seen in up to 30% of all breast cancers and is
enriched in certain phenotypes including basal-like (88%),
HER-2 amplified (50%) and luminal B (41%) (Bertheau et al.,
2013). In the luminal A sub-type, the incidence of p53 muta-
tion is low (17%) (Bertheau et al., 2013). Existing pre-clinical ev-
idence confirm that mutation in p53 is associated with
resistance to radiotherapy (Fei and El-Deiry, 2003; Gudkov
and Komarova, 2003). As expected, we observed that p53
Figure 4 e Blockade of CHK1 activation by V158411 and radio-potentiation. A. Representative western blot in MCF7 breast cancer cell line.
Expression of Chk1 and actin in untreated controls treated for 48 h, 5 days and 7 days, cells treated with scrambled siRNA for 48 h, 5 days and 7
days, and cells treated with Chk1 siRNA for 48 h, 5 days. Note no 7 day sample with Chk1 siRNA as insufficient cells alive to extract protein for
western blot analysis. B. Quantification CHK1 KD by siRNA in comparison to cell line samples treated with control scrambled siRNA. There was
80% KD after 48 h and more than 98% KD after 5 days. C. Clonogenic assays. In parallel with the samples prepared for western blotting a
clonogenic assay was performed in control cells, those treated with scrambled siRNA and with CHK1 siRNA for 48 h. This shows that there was
no clonogenic survival after 2 weeks in cells treated for 48 h with CHK1 siRNA. D. Dose dependent radiosensitisation of V158411in MCF-7 cells.
E. Dose dependent radiosensitisation of V158411in MDA-MB-231 cells. For all clonogenic assays, data are mean ± standard deviation from three
separate experiments in breast cancer cells. F. FACS profiles in MDA-MB-231 cells treated with VE158411 either alone or in combination with
IR.
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accumulation by IHC, a feature of mutant p53, was signifi-
cantly associated with early local recurrence. Taken together,
this provides clinical evidence that p53 is a marker of radio-
resistance in breast cancer.
Chk1 is a serine threonine protein kinase with critical roles
in genomic stability (Bartek and Lukas, 2003; Enders, 2008;
Zhang and Hunter, 2014). Under normal conditions, Chk1 is
expressed predominantly in the nucleus. Recent evidence
suggests that the sub-cellular localisation of CHK1 is tightly
regulated (Wang et al., 2012a). A key activator of Chk1 is ATR
which phosphorylates CHK1 at Serine345 and Serine317
(Cimprich and Cortez, 2008; Nam and Cortez, 2011; Smits
et al., 2010). Phosphorylated Chk1 is released from the
chromatin-enriched fractions into the soluble nucleus and
then to the cytoplasm. In addition, phosphorylation of Chk1
at Serine345 (pChk1) leads to its activation which not only pro-
motes further autophosphorylation at Serine296, but also re-
sults in phosphorylation and inactivation of Cdc25A and
Cdc25C. Whereas Cdc25A activates S-phase progression,
Cdc25C regulates mitotic entry through CDK1 (Cdc2)
(Cimprich and Cortez, 2008; Nam and Cortez, 2011; Smits
et al., 2010). In addition, pChk1 also targets many other pro-
teins involved in cell cycle regulation and DNA repair. For
example, phosphorylated Chk1 can activate Rad51-
dependent DNA damage repair by the high-fidelity homolo-
gous recombination pathway in the nucleus and inhibit cen-
trosomal cyclin B/Cdk1 activity and stabilize the mRNA in
the cytoplasm (Bartek and Lukas, 2003; Enders, 2008; Zhang
and Hunter, 2014). Chk1 is an important factor in determining
radio-sensitivity and Chk1 knockdown results in radio-
sensitisation (Wang et al., 2012b). In addition, Chk1 inhibition
by small molecule inhibitors potentiates cytotoxicity of radio-
therapy in pancreatic and nasopharyngeal cancer xenografts
(Feng et al., 2010; Morgan et al., 2010). In the current study,
we demonstrate that high levels of pChk1; a marker of func-
tional ATR-CHK1 pathway (Abdel-Fatah et al., 2015; Chen
et al., 2015), was significantly associated with shorter time to
local recurrence both in univariate and multivariate analyses.
Variations in the levels of pChk1 could not only relate to dif-
ferences in the activity of ATR but could also potentially reflect
variations in the expression of total Chk1 bearing a basal level
of serine345 phosphorylation. We therefore also investigated
total Chk1 expression but observed no significant associations
with time to local recurrence. Taken together the data suggest
that that pChk1 is a promising predictive biomarker. Emerging
data suggests that p53 and CHK1 link with each other. CHK1
can phosphorylate p53 and p53 can down-regulate CHK1
expression (Gottifredi et al., 2001; Ou et al., 2005). Accordingly,
in the current study we have shown that patients with tu-
mours expressing high levels of pChk1 and p53 were signifi-
cantly more at risk of local recurrence compared to those
with low levels of pChk1 and p53. This clinical data provides
evidence that P53eCHK1 expression status could be utilised
for radiotherapy stratification. In addition, we have also
shown that high levels of pChk1 and p53 was also associated
with shorter time to distant metastasis and BCSS implying
an aggressive biological phenotype. CHK1 targeting in p53
mutant cancer has recently emerged as a promising strategy
in breast cancer (Ma et al., 2012a). As the G1 check point
does not operate in p53 mutant tumours, cells are reliant
upon S and G2 checkpoints mediated through CHK1 for main-
taining genomic stability. When S and G2 checkpoints are
blocked by pharmacological inhibition of CHK1, p53 mutant
cells undergomitotic catastrophe and apoptosis. This targeted
approach was demonstrated recently in p53 mutant triple
negative breast cancer xenografts treated with CHK1 inhibitor
in combination with irinotecan chemotherapy (Ma et al.,
2012a). CHK1 inhibitors potentiated apoptosis and abrogated
cell-cycle arrest in irinotecan treated p53 mutant breast can-
cer xenografts and improved mice survival in that study (Ma
et al., 2012a). We have previously demonstrated that CHK1
mRNA overexpression is significantly linked to basal and
HER2þ phenotype (Abdel-Fatah et al., 2015). In addition, high
level of cytoplasmic pChk1 was also associated with basal
phenotype in that study (Abdel-Fatah et al., 2015). The data
in its entirety provides evidence that CHK1 and p53 are impor-
tant predictive biomarkers of early local recurrence, reflecting
breast cancer radio-resistance. However, a limitation to the
current clinical study is that it is retrospective. Patient in
this historical cohort received CMF chemotherapy and radia-
tion boost was not routinely delivered to most patients. A pro-
spective study in the context of modern adjuvant
chemotherapy and radiotherapy is warranted to confirm our
clinical observations.
To provide additional preclinical evidence, we investigated
the ability of ATR-CHK1 pathway modulation for radio-
sensitisation. First, ATR inhibition that prevents CHK1 activa-
tion lead to increased radio-sensitivity. Unexpectedly this was
more evident in p53 wild-type MCF-7 cells compared to p53
mutantMDA-MB-231 cells but consistent with previous obser-
vations in leukemia cell lines (Salovska et al., 2014; Vavrova
et al., 2013). Second, we observed radio-sensitisation using
VE158411, a CHK1 inhibitor. A previous study also reported
radiosensitisation in p53 mutant breast cancer cells using
AZD7762, another CHK1 inhibitor (Ma et al., 2012b). Although
radio-potentiation was more evident in MCF-7 cells, the
extent of radio-sensitisation by CHK1 inhibitor was compara-
tively less compared to ATR inhibitor. ATR inhibition besides
CHK1 activation could also block other HR related events,
contributing to additional IR toxicity. Taken together, these
data provide evidence that ATR-CHK1 blockade is a promising
radio-sensitisation strategy.
In conclusion, we have provided evidence that CHK1 and
p53 are predictive biomarker of radiotherapy resistance and
early local recurrence in breast cancer. ATR-CHK1 pathway
targeting is a promising personalised radiotherapy strategy.
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